miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

Take the Zacks Approach to Beat the Markets: Drilling Tools, Alcoa & Starbucks in Focus

View original at finance.yahoo.com
Take the Zacks Approach to Beat the Markets: Drilling Tools, Alcoa & Starbucks in Focus Major U.S. indexes like the Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average rallied 2.4%, 1.8%, and 1.3%, respectively, during holiday-shortened trading last week…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Zacks Top 10 portfolio returned +22.6% in 2025 vs. +17.9% for S&P 500 and +11.4% for equal-weight version

    80% confidence

  • Hypothetical equal-weight portfolio returned +22.4% in 2024 vs. +13.7% for the equal-weight S&P 500 index

    80% confidence

  • Over 10-year period (2016-2025), equal-weight Zacks Rank #1 stocks portfolio outperformed equal-weight S&P 500 by more than 7 percentage points (+18.55% vs. +11.65%)

    80% confidence

  • Zacks Focus List portfolio returned -15.2% in 2022 vs. S&P 500's -17.96%

    80% confidence

  • Zacks ECDP returned -2.1% in Q4 2025 vs. S&P 500's +2.7% gain and NOBL's +1.6% return

    80% confidence

  • Zacks ECAP portfolio returned -2.3% in Q4 2025 vs. S&P 500's +2.7% gain

    80% confidence

  • Suggested a collaborative framework for Greenland during World Economic Forum at Davos summit

    80% confidence

  • Zacks ECAP returned +16.26% in 2024 vs. +24.89% for S&P 500

    80% confidence

  • Equal-weight portfolio of Zacks Rank #1 stocks outperformed the equal-weight S&P 500 index by 7 percentage points (+17.81% vs. +10.85%)

    80% confidence

  • Zacks ECDP returned -0.6% in 2025 vs. +6.8% for NOBL

    80% confidence

  • Zacks Focus List portfolio returned +29.54% in 2023 vs. +26.28% for S&P 500 and +13.61% for equal-weight S&P 500

    80% confidence

  • Fresh tariff threats to countries opposing acquisition of Greenland

    80% confidence

  • Since 2012, Top 10 portfolio produced cumulative return of +2,472.7% vs. +561.6% for S&P 500 and +403.3% for equal-weight version

    80% confidence

  • Top 10 portfolio produced average annual return of +25.8% from 2012 through 2025 vs. +13.1% for S&P 500 and +10.5% for equal-weight version

    80% confidence

  • Zacks Focus List portfolio returned +22.1% in 2025 vs. +17.9% for the S&P 500 index and +11.4% for equal-weight version

    80% confidence

  • Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for S&P 500 and +13% for equal-weight S&P 500

    80% confidence

  • Zacks Top 10 portfolio returned +62.98% in 2024 vs. +25.04% for S&P 500 and +13% for equal-weight version

    80% confidence

  • Zacks ECAP returned -1.67% for full year 2025 vs. S&P 500's +17.9% gain

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Take the Zacks Approach to Beat the Markets: Drilling Tools, Alcoa & Starbucks in Focus — Source | Via News | es.VIA.NEWS